DUBAI, United Arab Emirates, Nov 30 (Bernama-BUSINESS WIRE) -- Three UAE government ministers will join ministers from the Association of South East Asian Nations (ASEAN) at the first ever Global Business Forum ASEAN, which takes place at Expo 2020 Dubai on December 8th- 9th.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005531/en/ Organised by Dubai Chamber in partnership with Expo 2020 Dubai, GBF ASEAN will be held under the theme The New Frontiers. The forum, featuring over 40 speakers and 25 panel discussions, will explore the changing dynamics of ASEAN countries and opportunities to increase bilateral trade, business and investment ties between the two regions. Representing the UAE at GBF ASEAN will be H.E Reem Al Hashemi, Minister of State for International Cooperation and Director General of Expo 2020 Dubai; H.E Omar Sultan Al Olama, Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications; and H.E. Dr Thani Al Zeyoudi, Minister of State for Foreign Trade. The three UAE ministers will be addressing the event alongside H.E. Abdul Aziz Al Ghurair, Chairman of the Board of Dubai Chambers and H.E. Hamad Buamim, President & CEO of Dubai Chamber. Government ministers from the ASEAN region participating at the forum include H.E Ramon Lopez, Secretary (Minister), Department of Trade & Industry, Republic of the Philippines; H.E William Dar, Secretary (Minister), Department of Agriculture, Republic of Philippines; H.E. Fortunato De La Pena, Secretary (Minister), Secretary of Science and Technology, Vice Chairman, Philippine Space Council, Republic of Philippines; H.E. Dato Lim Jock Hoi, Secretary General, ASEAN Secretariat; and Mohmed Razip Haji Hasan, Director General, Islamic Tourism Centre. “The line-up of high-calibre speakers reflects the strong commitment from the UAE and ASEAN countries in expanding economic cooperation and tapping into existing trade and investment synergies. There is vast potential to forge new partnerships between UAE businesses and their ASEAN counterparts and we look forward to exploring that at the upcoming forum,” said H.E. Hamad Buamim, President & CEO of Dubai Chamber. Editor’s note Established in 1965, the Dubai Chamber of Commerce & Industry is a non-profit public entity, whose mission is to represent, support and protect the interests of the business community in Dubai by creating a favourable business environment, supporting the development of business, and by promoting Dubai as an international business hub. *Source: AETOSWire View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005531/en/ Contact Ruba Abdel Halim Manager, PR & Corporate Communications, +97142028450 [email protected] Source : Dubai Chamber of Commerce & Industry --BERNAMA
0 Comments
KUALA LUMPUR, Nov 30 (Bernama) -- Toshiba Electronic Devices & Storage Corporation (Toshiba) has introduced two photocouplers, TLP5705H and TLP5702H’, housed in a thin SO6L package, for use as insulated gate drivers for small to medium capacity IGBTs/MOSFETs. Volume shipments begin today.
TLP5705H is Toshiba’s first product to deliver a peak output current rating of ±5.0A in a thin package (SO6L) only 2.3mm (max) high. As a result, devices such as small to medium capacity inverters and servo amplifiers that use a buffer circuit for current amplification can now drive their IGBTs/MOSFETs directly from the photocoupler, without any need of the buffer circuit. This will contribute to parts reduction and set miniaturisation. TLP5702H has a peak output current rating of ±2.5A. An SO6L package that can be mounted on the land pattern of Toshiba’s conventional SDIP6 package, facilitating easy replacement of Toshiba’s current products. The SO6L is thinner than SDIP6, which brings greater flexibility to component layouts on boards, and also allows it to be mounted on the back of a board or used where new circuit design imposes limits on available height. According to a statement, both photocouplers have a maximum operating temperature rating of 125ºC (Ta=-40 to 125ºC), making it easier to design and maintain temperature margins. Toshiba’s line-up also includes TLP5702H(LF4) and TLP5705H(LF4), housed in an SO6L(LF4) package as a lead-forming option. More at https://toshiba.semicon-storage.com/ap-en/top.html -- BERNAMA Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing
ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years WALTHAM, Mass., Nov 30 (Bernama-GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection. “The continued global scale of the COVID-19 pandemic has led to increased levels of immune pressure on the virus, which is driving the emergence of variants containing mutations associated with escape from common classes of neutralizing antibodies induced by natural infection or vaccination. Unlike most antibodies currently available under EUA, ADG20 has been shown to target an epitope that is highly conserved among clade I sarbecoviruses and that is not readily targeted by the endogenous neutralizing antibody response,” said Laura Walker, Ph.D., co-founder and chief scientific officer of Adagio. “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously. Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization. ADG20 was engineered for potent and broadly neutralizing activity in anticipation of both the rapid antigenic evolution of SARS-CoV-2 and the emergence of future SARS-like viruses with pandemic potential.” “ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection. We did this anticipating that SARS-CoV-2 would continue to evolve and potentially render some early therapies and vaccines obsolete,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our global clinical trials are advancing with potential EUA submissions in mid-2022 for both prevention and treatment of COVID-19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID-19 pandemic.” Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20’s utility in addressing this newly emerged variant of concern, including: · Conducting in vitro studies to evaluate the expected binding and neutralizing activity of ADG20 against Omicron. Initial data from these studies is anticipated by the end of the year; and · Recruiting patients in Adagio’s Phase 2/3 COVID-19 treatment trial, known as STAMP, across several clinical sites in South Africa (along with ongoing clinical trial efforts globally) in an effort to generate clinical data for ADG20 against infections due to the Omicron variant. Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS-CoV-2 and its variants of concern. ADG20 and Variants of Concern The neutralizing antibody response induced by SARS-CoV-2 infection and vaccination is dominated by three classes of receptor binding domain (RBD)-directed antibodies (Class 1, Class 2 and Class 3), which often share common escape mutations. The newly emerged Omicron (B.1.1.529) variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late-stage clinical development show they target one of these three dominant antigenic regions within the RBD. In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS-CoV-2 infection and vaccination. Thus, unlike many other clinical-stage antibodies, which were isolated from COVID-19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS-CoV-2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant. Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development. About ADG20 ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half-life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS-CoV-2 virus, SARS-CoV-2 variants of concern Alpha, Beta, Delta, and Gamma, other SARS-CoV-2 variants to date, and additional SARS-like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well-tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow-up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established. About Adagio Therapeutics Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the expected neutralizing activity of ADG20 against the Omicron variant; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the risk/benefit profile of our product candidates to patients; our manufacturing capabilities and strategy, including plans for doses available in the near future; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law. Contacts: Media Contact: Dan Budwick, 1AB [email protected] Investor Contact: Monique Allaire, THRUST Strategic Communications [email protected] Source: Adagio Therapeutics, Inc. --BERNAMA XIAMEN, China, Nov 29 (Bernama-BUSINESS WIRE) -- Xiamen’s marine economy is expected to embrace high-quality development during the 14th Five-Year Plan period (2021-25) as it has recently been guaranteed a leading city status in developing marine sectors in East China’s Fujian province.
The municipal government released two development plans, which noted that efforts should be made to enhance its role in bolstering the province's marine economy. According to the plans, Xiamen will set up strategic emerging marine industrial clusters by promoting the commercialization of scientific and technological achievements. Efforts will be made to speed up the construction of a national demonstration zone for the marine economy. Marine biological industries will also be cultivated, and build global supply bases for marine products. Xiamen will foster new drivers of growth for marine economy, such as building itself into a Southeast International Shipping Center and improving the efficiency of the ocean shipping transportation system. The plan noted that as of 2023, Xiamen will set up a modern marine industrial system supported by emerging marine industries, modern fisheries, port logistics, and high-end coastal tourism. The local government has also stepped up efforts to improve basic research capability, and build a batch of marine scientific research institution. A wide range of supportive measures have been rolled out to further stimulate the vitality of scientific and technological innovation. A high-tech industrial park for marine industry is expected to be built in Xiamen, which will push forward the development of high-end marine industries. Supported by strong scientific and technological prowess, the output value of Xiamen’s marine industry will reach 300 billion yuan by 2025, which is estimated to account for 30 percent of the city's total GDP. As a key port city of the 21st Century Maritime Silk Road, Xiamen will beef up efforts to attract world-class marine enterprises and core technologies, encourage Xiamen enterprises to go abroad, and deepen opening-up and cooperation in the marine economy. The city will develop itself into a world-class port, an international coastal tourism city, an ocean cultural exchange center for countries and regions involved in the Belt and Road Initiative, as well as a global model for marine ecological governance. View source version on businesswire.com: https://www.businesswire.com/news/home/20211126005477/en/ Contact Lorraine Yuan [email protected] 13911130781 Source : Xiamen Municipal People's Government --BERNAMA KUALA LUMPUR, Nov 26 -- Rise of Stars (ROS), a new mobile game that is being developed by LightCON, a subsidiary of WEMADE MAX, has opened its global teaser site. Under the slogan, ‘The 4x Blockchain Game for the Greatest Conqueror,’ the teaser site was designed to help users experience the unique atmosphere of ROS and the game concept with the representative image of the game. ROS is a new mobile SF strategy game featuring elaborately designed warships and planets set in the vast universe, according to a statement. It also has fun elements, such as for players to find planets with rich resources in the galaxy and engage in battles against opponents, in addition to the strategic planning to expand power through real-time massive warfare. At the same time, ROS will be building a system for players to obtain game tokens through resource mining within planets. Through the application of Wemade’s blockchain technology, ROS will introduce a new game token and also a non-fungible token (NFT) on WEMIX platform. Making every effort to ensure a successful global service launch in the first quarter of next year, ROS will release the game information and play videos sequentially following the opening of the teaser site. -- BERNAMA |
Archives
April 2023
|